HealthSanofi Ends Phase 1 Trial, Terminates SAR448272 Program, Nurix SaysBy Naomi CalderNov 5, 2026, 9:58 AM UTC
HealthMHRA May Review Non-OECD Non-Clinical Data in Individual Trial ApplicationsBy Naomi CalderNov 4, 2026, 10:55 PM UTC
HealthTRANSFORM II Finds Balloon Strategy Noninferior to Stents at 12 MonthsBy Naomi CalderNov 2, 2026, 12:22 PM UTC
HealthNovavax Reports $125 Million Milestone After Sanofi Trial DosingBy Naomi CalderOct 29, 2026, 6:23 PM UTC
HealthGenmab’s Cancer Combination Meets Both Primary Endpoints in Phase 3 TrialBy Naomi CalderOct 29, 2026, 12:09 AM UTC
BusinessNovartis Raises 2026 Core Operating Income Outlook After Q3 GrowthBy Helena WardOct 27, 2026, 6:18 AM UTC
HealthJohnson & Johnson Reports 75% Response Rate in 50-mg Phase 1 Prostate Cancer CohortBy Naomi CalderOct 26, 2026, 7:14 PM UTC
HealthBioNTech, DualityBio Say Breast Cancer Trial Met Goal Amid Lung Disease CasesBy Naomi CalderOct 26, 2026, 9:30 AM UTC
